Liso-cel vs Standard of Care With Salvage Chemotherapy Followed by ASCT as 2L Treatment in Patients With R/R LBCL: 3-year Follow-Up From Phase 3 TRANSFORM Study

home / between-the-lines / liso-cel-vs-standard-of-care-with-salvage-chemotherapy-followed-by-asct-as-2l-treatment-in

Experts discuss the 3-year follow-up results from the phase 3 TRANSFORM study, comparing liso-cel with standard of care with salvage chemotherapy followed by autologous stem cell transplant (ASCT) as second-line treatment in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Brief Overview of Current Treatment Landscape and Unmet Needs in R/R Large B-Cell Lymphoma

EP. 1: Brief Overview of Current Treatment Landscape and Unmet Needs in R/R Large B-Cell Lymphoma

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS
February 28th 2025

Experts provide a brief overview of the current treatment landscape and unmet needs in relapsed/refractory (R/R) large B-cell lymphoma.

Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data

EP. 2: Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data

Mazyar Shadman, MD, MPH;Melody Smith, MD, MS
February 28th 2025

Experts discuss the 3-year follow-up from the phase 3 TRANSFORM study, providing an overview of the study and key efficacy data.